254 related articles for article (PubMed ID: 18485575)
21. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
22. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.
Green SA; Alon A; Ianus J; McNaughton KS; Tozzi CA; Reiss TF
J Urol; 2006 Dec; 176(6 Pt 1):2535-40; discussion 2540. PubMed ID: 17085151
[TBL] [Abstract][Full Text] [Related]
26. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.
Rovner E; Kennelly M; Schulte-Baukloh H; Zhou J; Haag-Molkenteller C; Dasgupta P
Neurourol Urodyn; 2011 Apr; 30(4):556-62. PubMed ID: 21351127
[TBL] [Abstract][Full Text] [Related]
27. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
Steers W; Corcos J; Foote J; Kralidis G
BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
[TBL] [Abstract][Full Text] [Related]
28. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Costantini E; Lazzeri M
Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
[No Abstract] [Full Text] [Related]
29. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Soljanik I
Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
[No Abstract] [Full Text] [Related]
30. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
Takei M; Homma Y;
Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
[TBL] [Abstract][Full Text] [Related]
32. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
33. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
34. Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Lazzeri M
Eur Urol; 2009 Jul; 56(1):191-2. PubMed ID: 18485574
[No Abstract] [Full Text] [Related]
35. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
[TBL] [Abstract][Full Text] [Related]
36. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
37. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
[TBL] [Abstract][Full Text] [Related]
38. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
[TBL] [Abstract][Full Text] [Related]
39. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
